416 related articles for article (PubMed ID: 32248578)
1. Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.
Kari EJM; Kuusisto MEL; Honkavaara P; Hakalahti A; Haapasaari KM; Bloigu R; Karihtala P; Teppo HR; Pirinen R; Turpeenniemi-Hujanen T; Kuittinen O
Eur J Haematol; 2020 Aug; 105(2):156-163. PubMed ID: 32248578
[TBL] [Abstract][Full Text] [Related]
2. The average relative dose intensity of R-CHOP is an independent factor determining favorable overall survival in diffuse large B-cell lymphoma patients.
Długosz-Danecka M; Szmit S; Ogórka T; Skotnicki AB; Jurczak W
Cancer Med; 2019 Mar; 8(3):1103-1109. PubMed ID: 30740919
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Go SI; Park MJ; Song HN; Kim HG; Kang MH; Lee HR; Kim Y; Kim RB; Lee SI; Lee GW
J Cachexia Sarcopenia Muscle; 2016 Dec; 7(5):567-576. PubMed ID: 27104110
[TBL] [Abstract][Full Text] [Related]
4. Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.
Vähämurto P; Mannisto S; Pollari M; Karjalainen-Lindsberg ML; Mäkitie AA; Leppä S
Eur J Haematol; 2019 Jun; 102(6):457-464. PubMed ID: 30834564
[TBL] [Abstract][Full Text] [Related]
5. Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma.
Gang AO; Pedersen MØ; Knudsen H; Lauritzen AF; Pedersen M; Nielsen SL; Brown P; Høgdall E; Klausen TW; Nørgaard P
Leuk Lymphoma; 2015 Jul; 56(7):2039-46. PubMed ID: 25379621
[TBL] [Abstract][Full Text] [Related]
6. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
7. Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL.
Marshall S; Nishimura N; Inoue N; Yamauchi H; Tsuyama N; Takeuchi K; Mishima Y; Yokoyama M; Ogasawara T; Mori N; Ogawa T; Sakura H; Terui Y
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):162-169. PubMed ID: 33483276
[TBL] [Abstract][Full Text] [Related]
8. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).
Fridrik MA; Jaeger U; Petzer A; Willenbacher W; Keil F; Lang A; Andel J; Burgstaller S; Krieger O; Oberaigner W; Sihorsch K; Greil R
Eur J Cancer; 2016 May; 58():112-21. PubMed ID: 26990931
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness of rituximab and HIV on the survival of Ontario patients with diffuse large B-cell lymphoma.
Habbous S; Guo H; Beca J; Dai WF; Isaranuwatchai W; Cheung M; Chan KKW
Cancer Med; 2020 Oct; 9(19):7072-7082. PubMed ID: 32794362
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
11. A comparison of R-EPOCH and R-CHOP as a first-line regimen in de novo DLBCL patients with high Ki-67 expression in a single institution.
Huang JJ; Xia Y; Wang Y; Liu PP; Bi XW; Sun P; Lin TY; Jiang WQ; Li ZM
Oncotarget; 2016 Jul; 7(27):41242-41250. PubMed ID: 27183909
[TBL] [Abstract][Full Text] [Related]
12. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Dlouhy I; Karube K; Enjuanes A; Salaverria I; Nadeu F; Ramis-Zaldivar JE; Valero JG; Rivas-Delgado A; Magnano L; Martin-García D; Pérez-Galán P; Clot G; Rovira J; Jares P; Balagué O; Giné E; Mozas P; Briones J; Sancho JM; Salar A; Mercadal S; Alcoceba M; Valera A; Campo E; López-Guillermo A
Br J Haematol; 2022 Feb; 196(3):589-598. PubMed ID: 34632572
[TBL] [Abstract][Full Text] [Related]
13. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
[TBL] [Abstract][Full Text] [Related]
14. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
15. Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
Eyre TA; Martinez-Calle N; Hildyard C; Eyre DW; Plaschkes H; Griffith J; Wolf J; Fields PA; Gunawan A; Oliver R; Booth S; McMillan A; Fox CP; Bishton M; Collins GP; Hatton CSR
Br J Haematol; 2019 Aug; 186(4):e94-e98. PubMed ID: 31020646
[No Abstract] [Full Text] [Related]
16. Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.
Kurita D; Miura K; Nakagawa M; Ohtake S; Sakagami M; Uchino Y; Takahashi H; Kiso S; Hojo A; Kodaira H; Yagi M; Hirabayashi Y; Kobayashi Y; Iriyama N; Kobayashi S; Hatta Y; Kura Y; Sugitani M; Takei M
Int J Hematol; 2015 Jun; 101(6):585-93. PubMed ID: 25776837
[TBL] [Abstract][Full Text] [Related]
17. Rituximab, cyclophosphamide-fractionated, vincristine, doxorubicin and dexamethasone alternating with rituximab, methotrexate and cytarabine overcomes risk features associated with inferior outcomes in treatment of newly diagnosed, high-risk diffuse large B-cell lymphoma.
Mato A; Feldman T; Zielonka T; Singavi A; Gadaletta G; Waksmundzki K; Bhattacharyya P; Chow KF; Yang X; Panush D; Agress H; Rosario M; Howlett C; Pecora A; Goy A
Leuk Lymphoma; 2013 Dec; 54(12):2606-12. PubMed ID: 23488604
[TBL] [Abstract][Full Text] [Related]
18. Role of virological serum markers in patients with both hepatitis B virus infection and diffuse large B-cell lymphoma.
Zhou X; Wuchter P; Egerer G; Kriegsmann M; Mataityte A; Koelsche C; Witzens-Harig M; Kriegsmann K
Eur J Haematol; 2019 Oct; 103(4):410-416. PubMed ID: 31338887
[TBL] [Abstract][Full Text] [Related]
19. ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1.
Nowakowski GS; Zhu J; Zhang Q; Brody J; Sun X; Maly J; Song Y; Rizvi S; Song Y; Lansigan F; Jing H; Cao J; Lue JK; Luo W; Zhang L; Li L; Han I; Sun J; Jivani M; Liu Y; Heineman T; Smith SD
Future Oncol; 2020 May; 16(15):991-999. PubMed ID: 32250167
[TBL] [Abstract][Full Text] [Related]
20. A salvage chemotherapy of R-P-IMVP16/CBDCA consisting of rituximab, methylprednisolone, ifosfamide, methotrexate, etoposide, and carboplatin for patients with diffuse large B cell lymphoma who had previously received R-CHOP therapy as first-line chemotherapy.
Matsumoto T; Hara T; Shibata Y; Nakamura N; Nakamura H; Ninomiya S; Kitagawa J; Kanemura N; Goto N; Kito Y; Kasahara S; Yamada T; Sawada M; Miyazaki T; Takami T; Takeuchi T; Moriwaki H; Tsurumi H
Hematol Oncol; 2017 Sep; 35(3):288-295. PubMed ID: 26999778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]